This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jeffrey S. Schultz, MD; Jonathan A. Hoenig, MD; Howard Charles, MD
Bronx, NY

Arch Ophthalmol. 1993;111(12):1606-1607.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Metipranolol hydrochloride is a topical β blocker used in the treatment of glaucoma. It has been in widespread use throughout Europe since the late 1980s and has recently been introduced in the United States as OptiPranolol (Bausch and Lomb, Tampa, Fla). Adverse reactions to the British formulation of metipranolol (Glauline) (Smith and Nephew, Essex, England), including granulomatous anterior uveitis and/or blepharoconjunctivitis, have been recently described in the British literature.^1-3 The multidose preparations of metipranolol have been subsequently withdrawn from the European market. We report the first case of possible anterior uveitis secondary to metipranolol therapy.

Report of a Case.

The patient is a 79-year-old white woman with a 12-year history of treatment of primary open angle glaucoma. Her intraocular pressure (IOP) was initially controlled with 0.5% timolol maleate, but she subsequently required additional medical therapy (miotics and carbonic anhydrase inhibitors) along with laser trabeculoplasty in both eyes to control . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?